|
|
.
See Category: Neoplasms
See Header: Basal cell carcinoma of skin of other and unsp parts of face
ICD-10 (CM) Code and Descriptor
|
C44.319 |
Basal cell carcinoma of skin of other parts of face
|
C44319 utilizaton on OPPS claims.*
Primary
ICD10 Code |
ICD10
Position 2 |
ICD10
Position 3 |
ICD10
Position 4 |
ICD10
Position 5 |
ICD10
Position 6 |
ICD10
Position 7 |
ICD10
Position 8 |
ICD10
Position 9 |
ICD10
Position 10 |
| 61.82%
|
18.96%
|
6.60%
|
3.30%
|
2.27%
|
1.76%
|
1.48%
|
1.16%
|
0.86%
|
0.55%
|
* Medicare Part A utilization data is derived from the 100% 2023 Outpatient (Fee-for-Service) Standard Analytical File.
Commonly Associated Procedure Codes for C44.319*:
| CPT |
Description |
Number of Claims |
Sum Performed |
|
88305
|
TISSUE EXAM BY PATHOLOGIST |
18,020
|
25,618
|
|
17311
|
MOHS 1 STAGE H/N/HF/G |
12,790
|
13,362
|
|
G0463
|
HOSPITAL OUTPT CLINIC VISIT |
8,774
|
8,800
|
|
17312
|
MOHS ADDL STAGE |
5,395
|
6,614
|
|
13132
|
CMPLX RPR F/C/C/M/N/AX/G/H/F |
4,718
|
4,718
|
|
11102
|
TANGNTL BX SKIN SINGLE LES |
4,056
|
4,057
|
|
12052
|
INTMD RPR FACE/MM 2.6-5.0 CM |
4,023
|
4,025
|
|
88331
|
PATH CONSLTJ SURG 1 BLK 1SPC |
3,031
|
4,709
|
|
77412
|
RADIATION TX DELIVERY COMPLX |
2,940
|
2,943
|
|
17000
|
DESTRUCT PREMALG LESION |
2,123
|
2,124
|
|
J2704
|
INJ, PROPOFOL, 10 MG |
1,645
|
42,599
|
|
17003
|
DESTRUCT PREMALG LES 2-14 |
1,567
|
4,106
|
|
11642
|
EXC F/E/E/N/L MAL+MRG 1.1-2 |
1,527
|
1,550
|
|
11103
|
TANGNTL BX SKIN EA SEP/ADDL |
1,462
|
1,914
|
|
J3010
|
FENTANYL CITRATE INJECTION |
1,427
|
1,918
|
|
14040
|
TIS TRNFR F/C/C/M/N/A/G/H/F |
1,333
|
1,341
|
|
88332
|
PATH CONSLTJ SURG EA ADD BLK |
1,230
|
2,446
|
|
12051
|
INTMD RPR FACE/MM 2.5 CM/< |
1,186
|
1,186
|
|
J0690
|
CEFAZOLIN SODIUM INJECTION |
1,182
|
4,274
|
|
J2405
|
ONDANSETRON HCL INJECTION |
1,124
|
4,598
|
* Derived from 100% 2021 Outpatient (Fee-for-Service) Standard Analytical File.
C44.319 related to the following DRG Codes:
606-607
|
